Dysregulation of microtubules is commonly associated with several psychiatric and neurological disorders, including addiction and Alzheimer’s disease. Imaging of microtubules in vivo using positron emission tomography (PET) could provide valuable information on their role in the development of disease pathogenesis and aid in improving therapeutic regimens. We developed [¹¹C]MPC-6827, the first brain-penetrating PET radiotracer to image microtubules in vivo in the mouse brain. The aim of the present study was to assess the reproducibility of [¹¹C]MPC-6827 PET imaging in non-human primate brains. Two dynamic 0–120 min PET/CT imaging scans were performed in each of four healthy male cynomolgus monkeys approximately one week apart. Time activity curves (TACs) and standard uptake values (SUVs) were determined for whole brains and specific regions of the brains and compared between the “test” and “retest” data. [¹¹C]MPC-6827 showed excellent brain uptake with good pharmacokinetics in non-human primate brains, with significant correlation between the test and retest scan data (r = 0.77, p = 0.023). These initial evaluations demonstrate the high translational potential of [¹¹C]MPC-6827 to image microtubules in the brain in vivo in monkey models of neurological and psychiatric diseases.

Background: Microtubules (MTs) are critical for cell structure, function, and survival. MT instability may contribute to Alzheimer’s disease (AD) pathogenesis as evidenced by persistent negative regulation (phosphorylation) of the neuronal microtubule-associated protein tau. Hyperphosphorylated tau, not bound to MTs, forms intraneuronal pathology that correlates with dementia and can be tracked using positron emission tomography (PET) imaging. The contribution of MT instability in AD remains unknown, though it may be more proximal to neuronal dysfunction than tau accumulation. Our lab reported the first brain-penetrant MT-based PET ligand, [¹¹C]MPC-6827, and its PET imaging with this ligand in normal rodents and non-human primates demonstrated high brain uptake and excellent pharmacokinetics. Target engagement and mechanism of action using in vitro, in vivo, and ex vivo methods were evaluated here. Methods: In vitro cell uptake assay was performed in SH-SY5Y neuronal cells with [¹¹C]MPC-6827, with various MT stabilizing and destabilizing agents. To validate the in vitro results, wild type (WT) mice (n = 4) treated with a brain-penetrant MT stabilizing drug (EpoD) underwent microPET/CT brain imaging with [¹¹C]MPC-6827. To determine the influence of tau protein on radiotracer binding in the absence of protein accumulation, we utilized tau knockout (KO) mice. In vivo microPET imaging, ex vivo biodistribution, and autoradiography studies were performed in tau KO and WT mice (n = 6/group) with [¹¹C]MPC-6827. Additionally, α, β, and acetylated tubulin levels in both brain samples were determined using commercially available cytoskeleton-based MT kit and capillary electrophoresis immunoblotting assays. Results: Cell uptake demonstrated higher radioactive uptake with MT destabilizing agents and lower uptake with stabilizing agents compared to untreated cells. Similarly, acute treatment with EpoD in WT mice decreased [¹¹C]MPC-6827 brain uptake, assessed with microPET/CT imaging. Compared to WT mice, tau KO mice expressed significantly lower β tubulin, which contains the MPC-6827 binding domain, and modestly lower levels of acetylated α tubulin, indicative of unstable MTs. In vivo imaging revealed significantly higher [¹¹C]MPC-6827 uptake in tau KOs than WT, particularly in AD-relevant brain regions known to express high levels of tau. Ex vivo post-PET biodistribution and autoradiography confirmed the in vivo results. Conclusions: Collectively, our data indicate that [¹¹C]MPC-6827 uptake inversely correlates with MT stability and may better reflect the absence of tau than total tubulin levels. Given the radiotracer binding does not require the presence of aggregated tau, we hypothesize that [¹¹C]MPC-6827 may be particularly useful in preclinical stages of AD prior to tau deposition. Our study provides immediate clarity on high uptake of the MT-based radiotracer in AD brains, which directly informs clinical utility in MT/tau-based PET imaging studies.

Impairment and/or destabilization of neuronal microtubules (MTs) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including Alzheimer’s disease (AD), Parkinson’s disease and other neurological disorders. Increasing scientific evidence indicates that MT-stabilizing agents protect against the deleterious effects of neurodegeneration in treating AD. To quantify these protective benefits, we developed the first brain-penetrant PET radiopharmaceutical, [¹¹C]MPC-6827, for in vivo quantification of MTs in rodent and nonhuman primate models of AD. Mechanistic insights revealed from recently reported studies confirm the radiopharmaceutical’s high selectivity for destabilized MTs. To further translate it to clinical settings, its metabolic stability and pharmacokinetic parameters must be determined. Here, we report in vivo plasma and brain metabolism studies establishing the radiopharmaceutical-binding constants of [¹¹C]MPC-6827. Binding constants were extrapolated from autoradiography experiments; pretreatment with a nonradioactive MPC-6827 decreased the brain uptake >70%. It exhibited ideal binding characteristics (typical of a CNS radiopharmaceutical) including LogP (2.9), K_d (15.59 nM), and B_max (11.86 fmol/mg). Most important, [¹¹C]MPC-6827 showed high serum and metabolic stability (>95%) in rat plasma and brain samples.

Background: Brains affected by Alzheimer’s disease (AD) exhibit senile plaques containing amyloid beta (Aß) peptides and neurofibrillary tangles, formed when tau becomes hyperphosphorylated and disengages from microtubules (MTs). Early instability in MTs is observed in the AD process, emphasizing its significance in connecting the hallmark pathologies of Aß/tau‐based degenerative events. While current Aß and tau PET approaches can characterize disease lesions, they fall short in capturing earlier molecular events. MT‐PET aims to address this gap by targeting these early events, providing crucial insights into AD pathophysiology. The PET radiotracer, [11C]MPC‐6827, capable of tracking and quantifying MT‐based changes in real‐time and in vivo, addresses an urgent unmet need and facilitates the monitoring of MT changes in the early stages of AD. Here we present for the first time a comprehensive longitudinal PET imaging study of [11C]MPC‐6827 in Aß‐overexpressing (APP/PS1) and tau‐overexpressing (P301S) mouse models of AD.Methods: Longitudinal [11C]MPC‐6827 PET imaging, biodistribution studies, autoradiography, and behavioral assessments were conducted at multiple time points in APP/PS1 (3 to 22 mo old) and P301S (3 to 13‐mo‐old) transgenic (TG) and age‐matched wild‐type (WT) mice (n = 7/group). Whole‐brain standard uptake values for PET, %injected dose/gram for biodistribution, specific brain uptake for autoradiography, and nesting weight for cognitive assessments were determined and PET correlations for TG mice at different age‐points were calculated.Results: Longitudinal PET imaging demonstrated a 1.3‐fold (***p<0.0001) and 0.9‐fold (**p<0.005) higher brain uptake in APP/PS1 TG mice from 3 to 22 mo and P301S TG mice from 3 to 13 mo respectively (Fig1) and uptake increased with increasing Aß and tau loads in AD brains. Longitudinal PET data positively correlated with biodistribution (Pearson r = 0.94), and autoradiography results (r = 0.55) and negatively correlated with cognitive data (r = ‐0.65) in APP/PS1 mice (Fig2).Conclusion: Increased [11C]MPC‐6827 brain PET uptake with both increasing Aß and tau depositions longitudinally in AD brains (along with corroborating biodistribution and autoradiography results) clearly demonstrate the role of early MT dysregulations in Aß and tau‐based neurodegeneration processes. These findings highlight the potential of [11C]MPC‐6827 PET as a powerful tool for monitoring MT disintegration early‐on. Ongoing experiments are exploring translational potential in humans.

Background: Brains affected by Alzheimer's disease (AD) exhibit senile plaques containing amyloid beta (Aβ) peptides and neurofibrillary tangles, formed when tau becomes hyperphosphorylated and disengages from microtubules (MTs). Early instability in MTs is observed in the AD process, emphasizing its significance in connecting the hallmark pathologies of Aβ/tau‐based degenerative events. While current Aβ and tau PET approaches can characterize disease lesions, they fall short in capturing earlier molecular events. MT‐PET aims to address this gap by targeting these early events, providing crucial insights into AD pathophysiology. The PET radiotracer, [¹¹C]MPC‐6827, capable of tracking and quantifying MT‐based changes in real‐time and in vivo, addresses an urgent unmet need and facilitates the monitoring of MT changes in the early stages of AD. Here we present for the first time a comprehensive longitudinal PET imaging study of [¹¹C]MPC‐6827 in Aβ‐overexpressing (APP/PS1) and tau‐overexpressing (P301S) mouse models of AD.Methods: Longitudinal [¹¹C]MPC‐6827 PET imaging, biodistribution studies, autoradiography, and behavioral assessments were conducted at multiple time points in APP/PS1 (3 to 22 mo old) and P301S (3 to 13‐mo‐old ) transgenic (TG) and age‐matched wild‐type (WT) mice (n=7/group). Whole‐brain standard uptake values for PET, %injected dose/gram for biodistribution, specific brain uptake for autoradiography, and nesting weight for cognitive assessments were determined and PET correlations for TG mice at different age‐points were calculated.Results: Longitudinal PET imaging demonstrated a 1.3‐fold (***p<0.0001) and 0.9‐fold (**p<0.005) higher brain uptake in APP/PS1 TG mice from 3 to 22 mo and P301S TG mice from 3 to 13 mo respectively (Figure 1) and uptake increased with increasing Aβ and tau loads in AD brains. Longitudinal PET data positively correlated with biodistribution (Pearson r=0.94), and autoradiography results (r=0.55) and negatively correlated with cognitive data (r=‐0.65) in APP/PS1 mice (Figure 2).Conclusion: Increased [¹¹C]MPC‐6827 brain PET uptake with both increasing Aβ and tau depositions longitudinally in AD brains (along with corroborating biodistribution and autoradiography results) clearly demonstrate the role of early MT dysregulations in Aβ and tau‐based neurodegeneration processes. These findings highlight the potential of [¹¹C]MPC‐6827 PET as a powerful tool for monitoring MT disintegration early‐on. Ongoing experiments are exploring translational potential in humans.